In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

Researchers have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases. The study ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to ...

As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

They are important niches to the scientists who can now solve previously unsolvable problems, but they may not constitute ...

Insilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

President Sheinbaum shared a plan to strengthen Mexico's semiconductor industry and touched on GMO corn and the U.S. DEA on ...